SOLUTION GENTIAN VIOLET BPC

Indications

• Anesthesia (historically)
• Induction of dissociative anesthesia
• Research purposes in neuropharmacology

Dosage

Children: There are no established pediatric dosages for PCP, and its use in children is not recommended.

Adults: Dosage should be guided by clinical context and individual response, as this substance is not used in standard medical practice due to its potential for abuse and adverse effects.

Mechanism of action

PCP binds to a site within the ion channel of the NMDA receptor, blocking the influx of positive ions such as calcium and sodium. This inhibition prevents neuronal depolarization and disrupts normal neurotransmission, leading to its psychoactive effects. Additionally, PCP's interaction with the GluN2D subunit of the NMDA receptor has implications for its impact on motor function.

Pharmacodynamics

Phencyclidine exhibits its primary effects through NMDA receptor antagonism, leading to decreased excitatory neurotransmission in the brain. This results in a range of behavioral and physiological changes, including dissociation, hallucinations, and altered sensory perceptions. The drug's effects are dose-dependent and can lead to significant motor impairment due to its action on the NMDA receptor pathways.

Pharmacokinetics

PCP is rapidly absorbed and distributed throughout the body. It has a relatively high volume of distribution and is primarily metabolized in the liver. The elimination half-life can vary significantly but is generally in the range of several hours. PCP is excreted mainly in urine, and its metabolites can be detected for a prolonged period after use.

Pregnancy

There are no adequate studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether phencyclidine is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to specific product information for details on use as a coloring agent in formulations.

Adults: Refer to specific product information for details on use as a coloring agent in formulations.

Mechanism of action

The mechanism of action for violet dyes generally involves their ability to absorb specific wavelengths of light, which contributes to their coloring properties. In the context of pharmacology, they do not possess therapeutic effects but rather serve a functional role in drug formulation.

Pharmacodynamics

As a coloring agent, violet dyes do not exhibit pharmacodynamic properties associated with therapeutic agents. They do not interact with biological targets in the manner that active pharmaceutical ingredients do, and their primary role is to provide color rather than therapeutic efficacy.

Pharmacokinetics

Violet dyes, being non-active agents, do not undergo typical pharmacokinetic processes such as absorption, distribution, metabolism, and excretion in the same way that active drugs do. Their presence in formulations is primarily for aesthetic purposes, and they are typically excreted unchanged.

Pregnancy

Safety not established; consult healthcare provider.

Breast-feeding

Safety not established; consult healthcare provider.

Storage

Store in a cool, dry place, away from light.

Mechanism of action

The N-methyl-D-Aspartate (NMDA) receptor, a type of ionotropic receptor, is found on the dendrites of neurons and receives signals in the form of neurotransmitters. It is a major excitatory receptor in the brain. Normal physiological function requires that the activated receptor fluxes positive ions through the channel part of the receptor. PCP enters the ion channel from the outside of the neuron and binds, reversibly, to a site in the channel pore, blocking the flux of positive ions into the cell. PCP therefore inhibits depolarization of neurons and interferes with cognitive and other functions of the nervous system. Noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonists evoke a behavioral and neurobiological syndrome in experimental animals. We previously reported that phencyclidine (PCP), an NMDA receptor antagonist, increased locomotor activity in wildtype (WT) mice but not GluN2D subunit knockout mice. Thus, the aim of the present study was to determine whether the GluN2D subunit is involved in PCP-induced motor impairment. PCP or UBP141 (a GluN2D antagonist) induced potent motor impairment in WT mice but not GluN2D KO mice. By contrast, CIQ, a GluN2C/2D potentiator, induced severe motor impairment in GluN2D KO mice but not WT mice, suggesting that the GluN2D subunit plays an essential role in the effects of PCP and UBP141, and an appropriate balance between GluN2C and GluN2D subunits might be needed for appropriate motor performance. The level of the GluN2D subunit in the mature mouse brain is very low and restricted. GluN2D subunits exist in brainstem structures, the globus pallidus, thalamus, and subthalamic nucleus. We found that the expression of the c-fos gene increased the most among PCP-dependent differentially expressed genes between WT and GluN2D KO mice, and the number of Fos-positive cells increased after PCP administration in the basal ganglia motor circuit in WT mice but not GluN2D KO mice. These results suggest that the GluN2D subunit within the motor circuitry is a key subunit for PCP-induced motor impairment, which requires an intricate balance between GluN2C- and GluN2D-mediated excitatory outputs. Prepulse inhibition (PPI) is an example of sensorimotor gating and deficits in PPI have been demonstrated in schizophrenia patients. Phencyclidine (PCP) suppression of PPI in animals has been studied to elucidate the pathological elements of schizophrenia. However, the molecular mechanisms underlying PCP treatment or PPI in the brain are still poorly understood. In this study, quantitative phosphoproteomic analysis was performed on the prefrontal cortex from rats that were subjected to PPI after being systemically injected with PCP or saline. PCP downregulated phosphorylation events were significantly enriched in proteins associated with long-term potentiation (LTP). Importantly, this data set identifies functionally novel phosphorylation sites on known LTP-associated signaling molecules. In addition, mutagenesis of a significantly altered phosphorylation site on xCT (SLC7A11), the light chain of system xc-, the cystine/glutamate antiporter, suggests that PCP also regulates the activity of this protein. Finally, new insights were also derived on PPI signaling independent of PCP treatment. This is the first quantitative phosphorylation proteomic analysis providing new molecular insights into sensorimotor gating. Phencyclidine (PCP), a noncompetitive N-methyl-D-aspartate receptor antagonist, induces psychotomimetic effects in humans and animals. Administration of PCP to rodents is used as a preclinical model for schizophrenia; however, the molecular mechanisms underlying the symptoms remain largely unknown. Acute PCP treatment rapidly induces behavioral and cognitive deficits; therefore, post-translational regulation of protein activity is expected to play a role at early time points. We performed mass-spectrometry-driven quantitative analysis of rat frontal cortex 15, 30, or 240 min after the administ

Pharmacodynamics

Phencyclidine works primarily as an NMDA receptor antagonist, which blocks the activity of the NMDA Receptor.